At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 612 enrolled
Drug / intervention
Azilsartan medoxomil +3 moredrug
Likely dose
Valsartan 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Azilsartan medoxomil, Valsartan, and 2 other interventions for Essential Hypertension. Completed, enrolled 612 participants across 30 sites.
Detailed Summary
The purpose of this study is to evaluate the antihypertensive effect of azilsartan medoxomil compared with valsartan in Chinese participants with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartAug 2015
Primary CompletionSep 2017
Study CompletionOct 2017
TodayJul 2026
First PostedJun 24, 2015
Enrollment StartAug 27, 2015
Primary CompletionSep 22, 2017
Study CompletionOct 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.0 years ago
Interventions
Azilsartan medoxomildrug
Azilsartan medoxomil tablets
Valsartandrug
Valsartan 80 mg capsules
Azilsartan medoxomil Placebodrug
Azilsartan medoxomil placebo-matching tablets
Valsartan Placebodrug
Valsartan placebo-matching capsules